{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:34:36Z","timestamp":1774949676508,"version":"3.50.1"},"reference-count":6,"publisher":"SLACK, Inc.","issue":"S2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Refract Surg"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To compare visual outcomes using the Wave-Light ALLEGRETTO WAVE to administer either wavefrontoptimized (standard LASIK) or wavefront-guided (custom LASIK) treatments in myopic eyes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this prospective, open-label, multicenter study conducted in the United States, 374 eyes were randomized by alternating enrollment to receive either wavefront-optimized or wavefront-guided LASIK treatments with this laser platform. Bilateral treatments were administered, with both eyes of each patient receiving the same treatment. Corneal flaps were created using the IntraLase femtosecond laser.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In this FDA clinical trial, results at 3 months postoperatively revealed that 93% of eyes in both cohorts receiving either wavefront-optimized or wavefront-guided treatments attained an uncorrected visual acuity (UCVA) of 20\/20 or better. Seventy-six percent of eyes with the wavefront-optimized treatment and 64% of eyes with the wavefront-guided treatment achieved UCVA of 20\/16 or better. None of the eyes that received either treatment lost two lines or more of best spectacle-corrected visual acuity (BSCVA). In addition, 58% of eyes with wavefront-optimized treatment and 62% of eyes with wavefront-guided treatment gained one line or more of BSCVA. None of the eyes in either treatment group underwent retreatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n              In the majority of eyes, no statistically significant differences were found between either treatment group in regard to visual acuity and refractive outcomes. Wavefront-guided treatments are not required in most cases with this laser, but may be considered if the magnitude of preoperative root-mean-square (RMS) higher order aberrations is &gt;0.35 \u00b5m. In this study population, 83% of eyes had preoperative RMS higher order aberrations of &lt;0.3 \u00b5m. [\n              <jats:italic>J Refract Surg<\/jats:italic>\n              . 2008;24: S424\u2013S430.]\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/1081597x-20080401-20","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T21:26:04Z","timestamp":1549574764000},"source":"Crossref","is-referenced-by-count":64,"title":["Wavefront-optimized Versus Wavefront-guided LASIK for Myopic Astigmatism With the ALLEGRETTO WAVE: Three-month Results of a Prospective FDA Trial"],"prefix":"10.3928","volume":"24","author":[{"given":"Karl G.","family":"Stonecipher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy M.","family":"Kezirian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_2_2_2","unstructured":"Summary of Safety and Effectiveness for a Premarket Approval Application (for the wavefront-optimized correction of myopia with the ALLEGRETTO WAVE). Available at: http:\/\/www.fda.gov\/cdrh\/pdf2\/P020050b.pdf. Accessed February 2008."},{"key":"e_1_3_2_3_2","unstructured":"Summary of Safety and Effectiveness Data for a Supplemental Premarket Approval Application (for the wavefront-optimized correction of myopia with the ALLEGRETTO WAVE). Available at: http:\/\/www.fda.gov\/cdrh\/pdf2\/P020050S004b.pdf. Accessed February 2008."},{"key":"e_1_3_2_4_2","unstructured":"Summary of Safety and Effectiveness Data for a Supplemental Premarket Approval Application (VISX Star S4 Excimer Laser System and WaveScan WaveFront System). Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/dailys\/04\/july04\/072004\/03m-0333-cr00001-02-summaryofsafety-vol1.pdf. Accessed February 2008."},{"key":"e_1_3_2_5_2","unstructured":"Bausch & Lomb Incorporated Technolas 217z Zyoptix System for Personalized Vision Correction. Available at: http:\/\/www.fda.gov\/cdrh\/pdf\/P990027S006c.pdf. Accessed February 2008."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(98)80198-3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(99)00011-5"}],"container-title":["Journal of Refractive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/ophthalmology\/refractive-surgery\/journals\/jrs\/2008-4-24-4\/%7Bd141552f-9882-4562-bced-dc6dd3ac1d05%7D\/wavefront-optimized-versus-wavefront-guided-lasik-for-myopic-astigmatism-with-the-allegretto-wave-three-month-results-of-a-prospective-fda-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:19:24Z","timestamp":1728922764000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/1081597X-20080401-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":6,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.3928\/1081597X-20080401-20"],"URL":"https:\/\/doi.org\/10.3928\/1081597x-20080401-20","relation":{},"ISSN":["1081-597X"],"issn-type":[{"value":"1081-597X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}